Furthermore, the CD103+ CD8+ Trm subset in the tumor was associated with the anticancer response in patients with HNSCC and triple-negative breast cancer (TNBC) to ICB in combination with chemotherapy [80]. The gene discussed is CD8A; the disease is neoplasm.